API Holdings reported a significantly narrowed loss of Rs 29.6 crore for Q1 FY27, compared to Rs 145.4 crore a year earlier, alongside a 10% revenue increase and a return to positive EBITDA. The company has also cleared its debt of Rs 1,050 crore, marking a major milestone in its financial turnaround.
- Q1 FY27 loss narrowed from Rs 145.4 crore to Rs 29.6 crore
- Revenue rose 10% to Rs 1,754 crore; EBITDA turned positive at Rs 39.3 crore
- Company repaid Rs 1,050 crore debt, becoming debt-free
What happened
API Holdings, the Indian parent company of online pharmacy Pharmeasy and diagnostics provider Thyrocare, has revealed a considerable improvement in its Q1 FY27 financial results. The company reduced its net loss to Rs 29.6 crore from Rs 145.4 crore in the same quarter last year and reported a positive EBITDA of Rs 39.3 crore, a turnaround from an EBITDA loss of Rs 12.8 crore previously. Revenue increased by 10% to Rs 1,754 crore, driven by growth in both business-to-consumer and business-to-business segments.
A major highlight is the complete repayment of Rs 1,050 crore in debt, which has significantly strengthened API Holdings' balance sheet. This repayment was financed through the sale of a part of its stake in Thyrocare and internal accruals. The company also saw strong profitability gains in its key units, with Thyrocare's net profit rising by 34% to Rs 51.3 crore, while B2B operations, including medicine distributor Ascent, reported positive EBITDA after earlier losses.
Why it matters
The financial turnaround and debt clearance are critical for API Holdings as it navigates the competitive Indian healthcare and pharmacy landscape. The company had been under pressure for years due to heavy borrowing related to its acquisition of Thyrocare in 2021 and subsequent refinancing with high-interest loans. Successfully reducing losses and eliminating debt relieve this burden and provide greater operational flexibility.
Furthermore, positive EBITDA and revenue growth reflect improved operational efficiencies and stronger market positioning against competitors like Tata 1mg, Netmeds, and Apollo 247. By becoming debt-free, API Holdings is better placed to pursue growth initiatives, scale its platforms, and potentially revisit capital-raising plans that were postponed earlier due to financial constraints.
What to watch next
Going forward, market participants will be closely monitoring API Holdings' ability to sustain profitability and revenue momentum in both its retail pharmacy and diagnostic ventures. Continued expansion of its B2B segment, including the Ascent and Aknamed supply chain businesses, will also be key to securing diversified revenue streams and margin improvements.
Additionally, how the company leverages its now debt-free status to support strategic growth—whether through organic expansion, further acquisitions, or new capital inflows—will be critical for long-term success. Investors may also watch for updates on any planned IPO or secondary share initiatives after recent delays caused by past financial challenges.